<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03580967</url>
  </required_header>
  <id_info>
    <org_study_id>210161</org_study_id>
    <nct_id>NCT03580967</nct_id>
  </id_info>
  <brief_title>Vortioxetine Monotherapy for Major Depressive Disorder in Type 2 Diabetes</brief_title>
  <official_title>Vortioxetine Monotherapy for Major Depressive Disorder in Type 2 Diabetes: Role of Inflammation, Kynurenine Pathway, and Structural and Functional Brain Connectivity as Biomarkers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Todd Doyle</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Loyola University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will enroll participants who have been diagnosed with type 2 diabetes and are
      experiencing symptoms of depression. This study will look at an anti-depressant medication
      called vortioxetine (Trintellix). Vortioxetine is an oral medication (pill) that has been
      approved by the US Food and Drug Administration (FDA) to treat depression in adults.

      The purpose of this study is to look at what effects (if any) vortioxetine may have on
      symptoms of depression in patients with type 2 diabetes. This study will also look at what
      effects (if any) vortioxetine has on blood sugar, and how vortioxetine may improve the way
      our brains are able to adapt and respond to stress.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a 9-week, open-label, single-arm, pilot investigation for Type 2 Diabetes (T2D)
      patients with Major Depressive Disorder (MDD). The study includes a screening visit, a 1-week
      washout phase (or 30-day washout phase for serotonergic agents), and an 8-week flexible dose
      phase that includes the baseline and post-treatment follow-up visits. A minimum of N=70
      participants will be enrolled in the treatment.

      At the screening visit, the study will be explained and the informed consent process will
      take place. Patients who sign the IRB-approved consent form will undergo a psychiatric
      interview. The diagnosis of MDD will be established in this examination using the psychiatric
      interview and Hamilton Depression Rating Scale (HAM-D) by the study PI.

      Eligible participants will be instructed how to taper the antidepressant they have been
      taking (if relevant) over the course of the one-week (or 30-days for serotonergic agents).

      After these tapers, all participants will return for a baseline visit where they will be
      re-assessed to ensure persistent depressive symptoms. If patients continue to score ≥18 on
      the HAM-D, they will complete the psychosocial questionnaires; patients scoring below &lt;18 on
      the HAM-D at this visit will be terminated from the study and offered conventional, standard
      of care treatment within LUMC Department of Psychiatry. Once participants are given the
      psychosocial questionnaires as part of the baseline visit, a blood draw will be conducted by
      the Study Nurse/Coordinator, and MRI scans will be completed.

      At the end of the baseline session, participants will receive Vortioxetine for the remaining
      8-week flexible dosing period (i.e., 10 mg to 20 mg dosing). In the instance a patient is
      unable to tolerate either 10 mg to 20 mg of Vortioextine (as reported in the medication
      packet insert), the patient will be allowed to reduce their dosage to 5 mg, which will be
      done in consultation with the PI and sub-investigator.

      Following the 8-week intervention, participants will be scheduled for the post visit, which
      will include the following: another clinical interview and HAM-D conducted by the PI,
      completion of post visit-related psychosocial questionnaires, a second blood draw conducted
      by the Study Nurse/Coordinator, and then post visit-MRI scans will be completed. Should any
      patients continue to score &gt;18 on the HAM-D at study conclusion, resources and referrals will
      be provided for further psychological/psychiatric interventions, as needed.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2019</start_date>
  <completion_date type="Anticipated">August 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>All participants will receive a 10 or 20 mg dose of vortioxetine to take daily for 8 weeks. Study PI and sub-investigator (psychiatrist Murali Rao, MD) will determine appropriate dose.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in depressive symptoms measured by Hamilton Depression Rating Scale (HAM-D)</measure>
    <time_frame>Baseline and End of Treatment visit (Week 8)</time_frame>
    <description>The HAM-D is an 18-item questionnaire used to provide an indication of depression. The patient is rated by a clinician on 18 items scored on a 3-point or 5-point Likert-type scale. Remission of Major Depressive Disorder symptoms is defined as a total score on the HAM-D of ≤ 7.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Type2 Diabetes</condition>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Drug: Vortioxetine</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vortioxetine</intervention_name>
    <description>Oral pill to be taken daily for 8 weeks, 10 or 20 mg dosage. Participants who cannot tolerate this dose may be reduced to 5mg dose.</description>
    <arm_group_label>Drug: Vortioxetine</arm_group_label>
    <other_name>Trintellix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults 40 to 65 years of age at time of screening visit.

          -  Women only: Must be post-menopausal at time of screening visit (i.e., defined by NO
             menstruation for at least the past 12-months).

          -  Diagnosis of T2D, as defined by a diagnosis of T2D (for at least 12 months) in the
             medical record made by a physician (i.e., denoted as 250.XX according to ICD-9/ICD-10
             billing codes) OR

          -  current use of oral hypoglycemic medications or insulin OR

          -  having a fasting plasma glucose ≥126 mg/dL in the medical record OR

          -  having a 2-hour oral glucose tolerance test ≥200 mg/dL in the medical record

          -  Patients who meet criteria for current MDD without significant co-morbid psychiatric
             diagnoses, as determined by study PI from screening visit:

          -  Clinical Psychiatric Interview to determine DSM-V criteria for current MDD AND

          -  A minimum score of 18 on the Hamilton Depression Scale (HAM-D)

          -  Patients with T2D and current MDD that would benefit from antidepressant therapy,
             which may include:

          -  Patients with current MDD who were NOT prescribed an antidepressant medication in the
             past;

          -  Patients with current MDD who are NOT responding to their current prescribed
             antidepressant;

          -  Patients with current MDD who are experiencing breakthrough depressive symptoms
             despite being maintained on another antidepressant.

          -  Must have the ability to provide informed consent to participate in the study.

        Exclusion Criteria:

          -  Patients with any form of contraindication to Vortioxetine treatment, as outlined in
             the medication packet insert, (e.g., presence of a known hypersensitivity to the study
             drug or hypersensitivity to MAO-I use, etc.).

        MRI-Related Exclusion Criteria

          -  Participants weighing &gt;550 lbs (per MRI weight restrictions set by Loyola University
             Medical Center);

          -  Patients with a pacemaker, AICD, ossicular prosthesis, nerve stimulator, or another
             contraindication to MRI;

          -  Pregnant patients;

          -  Patients with an inability to tolerate being in enclosed places/spaces such as MRI;

          -  Patients with a history of neurosurgery, brain irradiation, or cerebral endovascular
             treatment.;

          -  Patients with history of epilepsy, stroke, neurodegenerative disorder, severe
             traumatic brain injury, hydrocephalus or demyelinating disorder;

          -  Patients with a history of malignant neoplasm

        Exclusion Criteria to Reduce False Positive Rates of Inflammation

          -  Specific pre-existing chronic pain conditions such as rheumatoid arthritis or
             fibromyalgia. However, this will NOT include more localized pain-related conditions
             such as low-back pain or complications associated with T2D (e.g., diabetic
             neuropathy).

          -  History of peptic ulcer complicated by perforation, hemorrhage, or obstruction;
             symptoms of peptic ulcer within 4 weeks of enrollment date that has not been treated.

          -  Current diagnosis of substance abuse/dependence during the 6 months prior to study
             enrollment.

          -  Current diagnosis of uncontrolled hypertension, anemia, liver disease, kidney disease,
             stroke, and autoimmune disease. Based on the clinical judgment of the study PI, a risk
             assessment will be conducted if a participant endorses any of these diagnoses but
             would be otherwise a suitable participant to enroll in the study.

          -  Current acute infection/infectious disease (i.e., a cold or the flu). Based on the
             clinical judgement of the study PI, a risk assessment will be conducted if a
             participant endorses some acute infection/infectious disease, but would be otherwise
             suitable to enroll in the study following a brief wait period for full symptom
             remission.

          -  Pre- and peri-menopausal women (i.e., defined as the presence of ANY menstruation
             within the past 12 months).

          -  Certain steroids (e.g., use of hormonal birth control) and any systemic
             corticosteroids. Please note that hormone replacement therapy will be allowed along
             with any topical corticosteroid creams.

          -  Patients currently enrolled in any other clinical trial for treatment of MDD (e.g.,
             patients receiving experimental vitamin D supplementation).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Todd Doyle, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Loyola University Chicago</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Todd Doyle, PhD</last_name>
    <phone>708-216-4303</phone>
    <email>todddoyle1@lumc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Todd Doyle, PhD</last_name>
      <phone>708-216-4303</phone>
      <email>todddoyle1@lumc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Centers for Disease Control and Prevention, National Diabetes Statistics Report. National diabetes statistics report. https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf. (2017).</citation>
  </reference>
  <reference>
    <citation>Anderson RJ, Freedland KE, Clouse RE, Lustman PJ. The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care. 2001 Jun;24(6):1069-78.</citation>
    <PMID>11375373</PMID>
  </reference>
  <reference>
    <citation>Gavard JA, Lustman PJ, Clouse RE. Prevalence of depression in adults with diabetes. An epidemiological evaluation. Diabetes Care. 1993 Aug;16(8):1167-78.</citation>
    <PMID>8375247</PMID>
  </reference>
  <reference>
    <citation>de Groot M, Doyle T, Hockman E, Wheeler C, Pinkerman B, Shubrook J, Gotfried R, Schwartz F. Depression among type 2 diabetes rural Appalachian clinic attendees. Diabetes Care. 2007 Jun;30(6):1602-4. Epub 2007 Mar 12.</citation>
    <PMID>17353505</PMID>
  </reference>
  <reference>
    <citation>Lustman PJ, Anderson RJ, Freedland KE, de Groot M, Carney RM, Clouse RE. Depression and poor glycemic control: a meta-analytic review of the literature. Diabetes Care. 2000 Jul;23(7):934-42.</citation>
    <PMID>10895843</PMID>
  </reference>
  <reference>
    <citation>de Groot M, Anderson R, Freedland KE, Clouse RE, Lustman PJ. Association of depression and diabetes complications: a meta-analysis. Psychosom Med. 2001 Jul-Aug;63(4):619-30.</citation>
    <PMID>11485116</PMID>
  </reference>
  <reference>
    <citation>Ciechanowski PS, Katon WJ, Russo JE. Depression and diabetes: impact of depressive symptoms on adherence, function, and costs. Arch Intern Med. 2000 Nov 27;160(21):3278-85.</citation>
    <PMID>11088090</PMID>
  </reference>
  <reference>
    <citation>Jacobson AM, de Groot M, Samson JA. The effects of psychiatric disorders and symptoms on quality of life in patients with type I and type II diabetes mellitus. Qual Life Res. 1997 Jan;6(1):11-20.</citation>
    <PMID>9062437</PMID>
  </reference>
  <reference>
    <citation>Egede LE, Osborn CY. Role of motivation in the relationship between depression, self-care, and glycemic control in adults with type 2 diabetes. Diabetes Educ. 2010 Mar-Apr;36(2):276-83. doi: 10.1177/0145721710361389. Epub 2010 Feb 23.</citation>
    <PMID>20179250</PMID>
  </reference>
  <reference>
    <citation>Katon W, von Korff M, Ciechanowski P, Russo J, Lin E, Simon G, Ludman E, Walker E, Bush T, Young B. Behavioral and clinical factors associated with depression among individuals with diabetes. Diabetes Care. 2004 Apr;27(4):914-20.</citation>
    <PMID>15047648</PMID>
  </reference>
  <reference>
    <citation>Katon WJ, Rutter C, Simon G, Lin EH, Ludman E, Ciechanowski P, Kinder L, Young B, Von Korff M. The association of comorbid depression with mortality in patients with type 2 diabetes. Diabetes Care. 2005 Nov;28(11):2668-72.</citation>
    <PMID>16249537</PMID>
  </reference>
  <reference>
    <citation>Egede LE, Zheng D, Simpson K. Comorbid depression is associated with increased health care use and expenditures in individuals with diabetes. Diabetes Care. 2002 Mar;25(3):464-70.</citation>
    <PMID>11874931</PMID>
  </reference>
  <reference>
    <citation>Baumeister H, Hutter N, Bengel J. Psychological and pharmacological interventions for depression in patients with diabetes mellitus and depression. Cochrane Database Syst Rev. 2012 Dec 12;12:CD008381. doi: 10.1002/14651858.CD008381.pub2. Review.</citation>
    <PMID>23235661</PMID>
  </reference>
  <reference>
    <citation>van der Feltz-Cornelis CM, Nuyen J, Stoop C, Chan J, Jacobson AM, Katon W, Snoek F, Sartorius N. Effect of interventions for major depressive disorder and significant depressive symptoms in patients with diabetes mellitus: a systematic review and meta-analysis. Gen Hosp Psychiatry. 2010 Jul-Aug;32(4):380-95. doi: 10.1016/j.genhosppsych.2010.03.011. Epub 2010 May 15. Review. Erratum in: Gen Hosp Psychiatry. 2010 Nov-Dec;32(6):645.</citation>
    <PMID>20633742</PMID>
  </reference>
  <reference>
    <citation>Champaneri S, Wand GS, Malhotra SS, Casagrande SS, Golden SH. Biological basis of depression in adults with diabetes. Curr Diab Rep. 2010 Dec;10(6):396-405. doi: 10.1007/s11892-010-0148-9. Review.</citation>
    <PMID>20878274</PMID>
  </reference>
  <reference>
    <citation>Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008 Jan;9(1):46-56. Review.</citation>
    <PMID>18073775</PMID>
  </reference>
  <reference>
    <citation>Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry. 2009 May 1;65(9):732-41. doi: 10.1016/j.biopsych.2008.11.029. Epub 2009 Jan 15. Review.</citation>
    <PMID>19150053</PMID>
  </reference>
  <reference>
    <citation>Stuart MJ, Baune BT. Depression and type 2 diabetes: inflammatory mechanisms of a psychoneuroendocrine co-morbidity. Neurosci Biobehav Rev. 2012 Jan;36(1):658-76. doi: 10.1016/j.neubiorev.2011.10.001. Epub 2011 Oct 14. Review.</citation>
    <PMID>22020230</PMID>
  </reference>
  <reference>
    <citation>Pickup JC. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care. 2004 Mar;27(3):813-23. Review.</citation>
    <PMID>14988310</PMID>
  </reference>
  <reference>
    <citation>de Jonge P, Rosmalen JG. Comment on: Knol MJ, Twisk JWR, Beekman ATF, Heine RJ, Snoek FJ, Pouwer F. (2006) depression as a risk factor for the onset of type 2 diabetes mellitus. A meta-analysis. Diabetologia; 49: 837-845. Diabetologia. 2006 Nov;49(11):2797-8; author reply 2799-800. Epub 2006 Aug 18.</citation>
    <PMID>16917758</PMID>
  </reference>
  <reference>
    <citation>Ruhé HG, Mason NS, Schene AH. Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies. Mol Psychiatry. 2007 Apr;12(4):331-59. Epub 2007 Jan 16. Review.</citation>
    <PMID>17389902</PMID>
  </reference>
  <reference>
    <citation>Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 2006 Jan;27(1):24-31. Epub 2005 Nov 28. Review.</citation>
    <PMID>16316783</PMID>
  </reference>
  <reference>
    <citation>Doyle TA, de Groot M, Harris T, Schwartz F, Strotmeyer ES, Johnson KC, Kanaya A. Diabetes, depressive symptoms, and inflammation in older adults: results from the Health, Aging, and Body Composition Study. J Psychosom Res. 2013 Nov;75(5):419-24. doi: 10.1016/j.jpsychores.2013.08.006. Epub 2013 Aug 16.</citation>
    <PMID>24182629</PMID>
  </reference>
  <reference>
    <citation>Alvarez A, Faccioli J, Guinzbourg M, Castex MM, Bayón C, Masson W, Bluro I, Kozak A, Sorroche P, Capurro L, Grosembacher L, Proietti A, Finkelsztein C, Costa L, Fainstein Day P, Cagide A, Litwak LE, Golden SH. Endocrine and inflammatory profiles in type 2 diabetic patients with and without major depressive disorder. BMC Res Notes. 2013 Feb 14;6:61. doi: 10.1186/1756-0500-6-61.</citation>
    <PMID>23410093</PMID>
  </reference>
  <reference>
    <citation>Hood KK, Lawrence JM, Anderson A, Bell R, Dabelea D, Daniels S, Rodriguez B, Dolan LM; SEARCH for Diabetes in Youth Study Group. Metabolic and inflammatory links to depression in youth with diabetes. Diabetes Care. 2012 Dec;35(12):2443-6. doi: 10.2337/dc11-2329. Epub 2012 Oct 1.</citation>
    <PMID>23033243</PMID>
  </reference>
  <reference>
    <citation>Yoshimura R, Hori H, Ikenouchi-Sugita A, Umene-Nakano W, Ueda N, Nakamura J. Higher plasma interleukin-6 (IL-6) level is associated with SSRI- or SNRI-refractory depression. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Jun 15;33(4):722-6. doi: 10.1016/j.pnpbp.2009.03.020. Epub 2009 Mar 28.</citation>
    <PMID>19332097</PMID>
  </reference>
  <reference>
    <citation>Myint AM, Kim YK. Cytokine-serotonin interaction through IDO: a neurodegeneration hypothesis of depression. Med Hypotheses. 2003 Nov-Dec;61(5-6):519-25.</citation>
    <PMID>14592780</PMID>
  </reference>
  <reference>
    <citation>Munipally PK, Agraharm SG, Valavala VK, Gundae S, Turlapati NR. Evaluation of indoleamine 2,3-dioxygenase expression and kynurenine pathway metabolites levels in serum samples of diabetic retinopathy patients. Arch Physiol Biochem. 2011 Dec;117(5):254-8. doi: 10.3109/13813455.2011.623705. Epub 2011 Oct 29.</citation>
    <PMID>22034910</PMID>
  </reference>
  <reference>
    <citation>Doyle T, Halaris A, Rao M. Shared neurobiological pathways between type 2 diabetes and depressive symptoms: a review of morphological and neurocognitive findings. Curr Diab Rep. 2014 Dec;14(12):560. doi: 10.1007/s11892-014-0560-7. Review.</citation>
    <PMID>25381209</PMID>
  </reference>
  <reference>
    <citation>Fossati P, Radtchenko A, Boyer P. Neuroplasticity: from MRI to depressive symptoms. Eur Neuropsychopharmacol. 2004 Dec;14 Suppl 5:S503-10. Review.</citation>
    <PMID>15550349</PMID>
  </reference>
  <reference>
    <citation>Reagan LP. Diabetes as a chronic metabolic stressor: causes, consequences and clinical complications. Exp Neurol. 2012 Jan;233(1):68-78. doi: 10.1016/j.expneurol.2011.02.004. Epub 2011 Feb 12. Review.</citation>
    <PMID>21320489</PMID>
  </reference>
  <reference>
    <citation>Ho N, Sommers MS, Lucki I. Effects of diabetes on hippocampal neurogenesis: links to cognition and depression. Neurosci Biobehav Rev. 2013 Sep;37(8):1346-62. doi: 10.1016/j.neubiorev.2013.03.010. Epub 2013 May 13. Review.</citation>
    <PMID>23680701</PMID>
  </reference>
  <reference>
    <citation>Maes M, Yirmyia R, Noraberg J, Brene S, Hibbeln J, Perini G, Kubera M, Bob P, Lerer B, Maj M. The inflammatory &amp; neurodegenerative (I&amp;ND) hypothesis of depression: leads for future research and new drug developments in depression. Metab Brain Dis. 2009 Mar;24(1):27-53. doi: 10.1007/s11011-008-9118-1. Epub 2008 Dec 16. Review.</citation>
    <PMID>19085093</PMID>
  </reference>
  <reference>
    <citation>Koehl M, Abrous DN. A new chapter in the field of memory: adult hippocampal neurogenesis. Eur J Neurosci. 2011 Mar;33(6):1101-14. doi: 10.1111/j.1460-9568.2011.07609.x. Review.</citation>
    <PMID>21395854</PMID>
  </reference>
  <reference>
    <citation>Snyder JS, Hong NS, McDonald RJ, Wojtowicz JM. A role for adult neurogenesis in spatial long-term memory. Neuroscience. 2005;130(4):843-52.</citation>
    <PMID>15652983</PMID>
  </reference>
  <reference>
    <citation>Ajilore O, Narr K, Rosenthal J, Pham D, Hamilton L, Watari K, Elderkin-Thompson V, Darwin C, Toga A, Kumar A. Regional cortical gray matter thickness differences associated with type 2 diabetes and major depression. Psychiatry Res. 2010 Nov 30;184(2):63-70. doi: 10.1016/j.pscychresns.2010.07.003. Epub 2010 Sep 15.</citation>
    <PMID>20832254</PMID>
  </reference>
  <reference>
    <citation>Kumar A, Gupta R, Thomas A, Ajilore O, Hellemann G. Focal subcortical biophysical abnormalities in patients diagnosed with type 2 diabetes and depression. Arch Gen Psychiatry. 2009 Mar;66(3):324-30. doi: 10.1001/archgenpsychiatry.2008.548.</citation>
    <PMID>19255382</PMID>
  </reference>
  <reference>
    <citation>Kumar A, Haroon E, Darwin C, Pham D, Ajilore O, Rodriguez G, Mintz J. Gray matter prefrontal changes in type 2 diabetes detected using MRI. J Magn Reson Imaging. 2008 Jan;27(1):14-9.</citation>
    <PMID>18050330</PMID>
  </reference>
  <reference>
    <citation>Awad N, Gagnon M, Messier C. The relationship between impaired glucose tolerance, type 2 diabetes, and cognitive function. J Clin Exp Neuropsychol. 2004 Nov;26(8):1044-80. Review.</citation>
    <PMID>15590460</PMID>
  </reference>
  <reference>
    <citation>Connolly KR, Thase ME. Vortioxetine: a New Treatment for Major Depressive Disorder. Expert Opin Pharmacother. 2016;17(3):421-31. doi: 10.1517/14656566.2016.1133588. Review.</citation>
    <PMID>26679430</PMID>
  </reference>
  <reference>
    <citation>Bang-Andersen B, Ruhland T, Jørgensen M, Smith G, Frederiksen K, Jensen KG, Zhong H, Nielsen SM, Hogg S, Mørk A, Stensbøl TB. Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem. 2011 May 12;54(9):3206-21. doi: 10.1021/jm101459g. Epub 2011 Apr 12.</citation>
    <PMID>21486038</PMID>
  </reference>
  <reference>
    <citation>Mørk A, Pehrson A, Brennum LT, Nielsen SM, Zhong H, Lassen AB, Miller S, Westrich L, Boyle NJ, Sánchez C, Fischer CW, Liebenberg N, Wegener G, Bundgaard C, Hogg S, Bang-Andersen B, Stensbøl TB. Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder. J Pharmacol Exp Ther. 2012 Mar;340(3):666-75. doi: 10.1124/jpet.111.189068. Epub 2011 Dec 9.</citation>
    <PMID>22171087</PMID>
  </reference>
  <reference>
    <citation>Westrih I, Rehrson A, &amp; Zhong H, et al. In vitro and in vivo effects for the multimodal antidepressant vortioxetine (Lu AA21004) at human and rat targets. International Journal of Psychiatry and Clinical Practice 2012; 16 (S1): 47.</citation>
  </reference>
  <reference>
    <citation>Florea I, Loft H, Danchenko N, Rive B, Brignone M, Merikle E, Jacobsen PL, Sheehan DV. The effect of vortioxetine on overall patient functioning in patients with major depressive disorder. Brain Behav. 2017 Feb 2;7(3):e00622. doi: 10.1002/brb3.622. eCollection 2017 Mar.</citation>
    <PMID>28293465</PMID>
  </reference>
  <reference>
    <citation>McIntyre RS, Harrison J, Loft H, Jacobson W, Olsen CK. The Effects of Vortioxetine on Cognitive Function in Patients with Major Depressive Disorder: A Meta-Analysis of Three Randomized Controlled Trials. Int J Neuropsychopharmacol. 2016 Jun 15;19(10). pii: pyw055. doi: 10.1093/ijnp/pyw055.</citation>
    <PMID>27312740</PMID>
  </reference>
  <reference>
    <citation>Nomikos GG, Tomori D, Zhong W, Affinito J, Palo W. Efficacy, safety, and tolerability of vortioxetine for the treatment of major depressive disorder in patients aged 55 years or older. CNS Spectr. 2017 Aug;22(4):348-362. doi: 10.1017/S1092852916000626. Epub 2016 Nov 21.</citation>
    <PMID>27869048</PMID>
  </reference>
  <reference>
    <citation>de Groot M, Doyle T, Kushnick M, Shubrook J, Merrill J, Rabideau E, Schwartz F. Can lifestyle interventions do more than reduce diabetes risk? Treating depression in adults with type 2 diabetes with exercise and cognitive behavioral therapy. Curr Diab Rep. 2012 Apr;12(2):157-66. doi: 10.1007/s11892-012-0261-z.</citation>
    <PMID>22350739</PMID>
  </reference>
  <reference>
    <citation>Calabrese JR, Skwerer RG, Barna B, Gulledge AD, Valenzuela R, Butkus A, Subichin S, Krupp NE. Depression, immunocompetence, and prostaglandins of the E series. Psychiatry Res. 1986 Jan;17(1):41-7.</citation>
    <PMID>2935897</PMID>
  </reference>
  <reference>
    <citation>Funakoshi-Tago M, Shimizu T, Tago K, Nakamura M, Itoh H, Sonoda Y, Kasahara T. Celecoxib potently inhibits TNFalpha-induced nuclear translocation and activation of NF-kappaB. Biochem Pharmacol. 2008 Sep 1;76(5):662-71. doi: 10.1016/j.bcp.2008.06.015. Epub 2008 Jul 3.</citation>
    <PMID>18644347</PMID>
  </reference>
  <reference>
    <citation>Hayashino Y, Mashitani T, Tsujii S, Ishii H; Diabetes Distress and Care Registry at Tenri Study Group. Elevated levels of hs-CRP are associated with high prevalence of depression in japanese patients with type 2 diabetes: the Diabetes Distress and Care Registry at Tenri (DDCRT 6). Diabetes Care. 2014 Sep;37(9):2459-65. doi: 10.2337/dc13-2312. Epub 2014 Jun 26.</citation>
    <PMID>24969579</PMID>
  </reference>
  <reference>
    <citation>Husain MM, Rush AJ, Trivedi MH, McClintock SM, Wisniewski SR, Davis L, Luther JF, Zisook S, Fava M. Pain in depression: STAR*D study findings. J Psychosom Res. 2007 Aug;63(2):113-22.</citation>
    <PMID>17662746</PMID>
  </reference>
  <reference>
    <citation>Lanquillon S, Krieg JC, Bening-Abu-Shach U, Vedder H. Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology. 2000 Apr;22(4):370-9.</citation>
    <PMID>10700656</PMID>
  </reference>
  <reference>
    <citation>Leuchter AF, Husain MM, Cook IA, Trivedi MH, Wisniewski SR, Gilmer WS, Luther JF, Fava M, Rush AJ. Painful physical symptoms and treatment outcome in major depressive disorder: a STAR*D (Sequenced Treatment Alternatives to Relieve Depression) report. Psychol Med. 2010 Feb;40(2):239-51. doi: 10.1017/S0033291709006035. Epub 2009 Jun 3.</citation>
    <PMID>19493369</PMID>
  </reference>
  <reference>
    <citation>Lieb J, Karmali R, Horrobin D. Elevated levels of prostaglandin E2 and thromboxane B2 in depression. Prostaglandins Leukot Med. 1983 Apr;10(4):361-7.</citation>
    <PMID>6574523</PMID>
  </reference>
  <reference>
    <citation>Miller CL, Llenos IC, Dulay JR, Weis S. Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder. Brain Res. 2006 Feb 16;1073-1074:25-37. Epub 2006 Jan 30.</citation>
    <PMID>16448631</PMID>
  </reference>
  <reference>
    <citation>Miller GE, Rohleder N, Cole SW. Chronic interpersonal stress predicts activation of pro- and anti-inflammatory signaling pathways 6 months later. Psychosom Med. 2009 Jan;71(1):57-62. doi: 10.1097/PSY.0b013e318190d7de. Epub 2008 Dec 10.</citation>
    <PMID>19073750</PMID>
  </reference>
  <reference>
    <citation>Myint AM, Kim YK, Verkerk R, Park SH, Scharpé S, Steinbusch HW, Leonard BE. Tryptophan breakdown pathway in bipolar mania. J Affect Disord. 2007 Sep;102(1-3):65-72. Epub 2007 Jan 30.</citation>
    <PMID>17270276</PMID>
  </reference>
  <reference>
    <citation>Myint AM, Kim YK, Verkerk R, Scharpé S, Steinbusch H, Leonard B. Kynurenine pathway in major depression: evidence of impaired neuroprotection. J Affect Disord. 2007 Feb;98(1-2):143-51. Epub 2006 Sep 6.</citation>
    <PMID>16952400</PMID>
  </reference>
  <reference>
    <citation>O'Brien SM, Scully P, Fitzgerald P, Scott LV, Dinan TG. Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy. J Psychiatr Res. 2007 Apr-Jun;41(3-4):326-31. Epub 2006 Jul 25.</citation>
    <PMID>16870211</PMID>
  </reference>
  <reference>
    <citation>Pilowsky I, Spence N, Cobb J, Katsikitis M. The Illness Behavior Questionnaire as an aid to clinical assessment. Gen Hosp Psychiatry. 1984 Apr;6(2):123-30.</citation>
    <PMID>6714666</PMID>
  </reference>
  <reference>
    <citation>Riondino S, Trifirò E, Principessa L, Mascioletti S, Di Renzo L, Gaudio C, Biasucci LM, Crea F, Pulcinelli FM. Lack of biological relevance of platelet cyclooxygenase-2 dependent thromboxane A2 production. Thromb Res. 2008;122(3):359-65. doi: 10.1016/j.thromres.2007.12.011. Epub 2008 Mar 4.</citation>
    <PMID>18295304</PMID>
  </reference>
  <reference>
    <citation>Rosenbaum D, Haipt A, Fuhr K, Haeussinger FB, Metzger FG, Nuerk HC, Fallgatter AJ, Batra A, Ehlis AC. Aberrant functional connectivity in depression as an index of state and trait rumination. Sci Rep. 2017 May 19;7(1):2174. doi: 10.1038/s41598-017-02277-z.</citation>
    <PMID>28526867</PMID>
  </reference>
  <reference>
    <citation>Drysdale AT, Grosenick L, Downar J, Dunlop K, Mansouri F, Meng Y, Fetcho RN, Zebley B, Oathes DJ, Etkin A, Schatzberg AF, Sudheimer K, Keller J, Mayberg HS, Gunning FM, Alexopoulos GS, Fox MD, Pascual-Leone A, Voss HU, Casey BJ, Dubin MJ, Liston C. Resting-state connectivity biomarkers define neurophysiological subtypes of depression. Nat Med. 2017 Jan;23(1):28-38. doi: 10.1038/nm.4246. Epub 2016 Dec 5. Erratum in: Nat Med. 2017 Feb 7;23 (2):264.</citation>
    <PMID>27918562</PMID>
  </reference>
  <reference>
    <citation>Cohen, J. (1988). Statistical Power Analyses for the Behavioral Sciences (2nd Edition). Psychology Press. Taylor &amp; Francis Group.</citation>
  </reference>
  <reference>
    <citation>de Groot M, Doyle T, Averyt J, Risaliti C, Shubroo J. Depressive symptoms and type 2 diabetes mellitus in rural appalachia: an 18-month follow-up study. Int J Psychiatry Med. 2015;48(4):263-77. doi: 10.2190/PM.48.4.c.</citation>
    <PMID>25817523</PMID>
  </reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>June 25, 2018</study_first_submitted>
  <study_first_submitted_qc>July 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 10, 2018</study_first_posted>
  <last_update_submitted>October 22, 2019</last_update_submitted>
  <last_update_submitted_qc>October 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Loyola University</investigator_affiliation>
    <investigator_full_name>Todd Doyle</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Type 2 Diabetes</keyword>
  <keyword>Major Depressive Disorder</keyword>
  <keyword>Vortioxetine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vortioxetine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

